[go: up one dir, main page]

CL2013003618A1 - Formulacion liofilizada de factor de crecimiento de fibroblastos 18 (fgf-18); método para producir la formulación; artículo de manufactura. - Google Patents

Formulacion liofilizada de factor de crecimiento de fibroblastos 18 (fgf-18); método para producir la formulación; artículo de manufactura.

Info

Publication number
CL2013003618A1
CL2013003618A1 CL2013003618A CL2013003618A CL2013003618A1 CL 2013003618 A1 CL2013003618 A1 CL 2013003618A1 CL 2013003618 A CL2013003618 A CL 2013003618A CL 2013003618 A CL2013003618 A CL 2013003618A CL 2013003618 A1 CL2013003618 A1 CL 2013003618A1
Authority
CL
Chile
Prior art keywords
formulation
fgf
growth factor
fibroblast growth
article
Prior art date
Application number
CL2013003618A
Other languages
English (en)
Inventor
Alessandra Cerreti
Rio Alessandra Del
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47356563&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013003618(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of CL2013003618A1 publication Critical patent/CL2013003618A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención se refiere al campo de las formulaciones farmacéuticas. Más particularmente se dirige a formulaciones de compuesto de Factor de Crecimiento de Fibroblastos 18 (18-FGF) y a métodos de producción de tales formulaciones liofilizadas. Las formulaciones liofilizadas de acuerdo con la invención son estables durante el almacenamiento durante un período adecuado de tiempo. Se pueden utilizar, después de la reconstitución, para el tratamiento de trastornos del cartílago, tales como osteoartritis o lesiones del cartílago.
CL2013003618A 2011-06-17 2013-12-17 Formulacion liofilizada de factor de crecimiento de fibroblastos 18 (fgf-18); método para producir la formulación; artículo de manufactura. CL2013003618A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11170437 2011-06-17
US201161499216P 2011-06-21 2011-06-21

Publications (1)

Publication Number Publication Date
CL2013003618A1 true CL2013003618A1 (es) 2014-07-04

Family

ID=47356563

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013003618A CL2013003618A1 (es) 2011-06-17 2013-12-17 Formulacion liofilizada de factor de crecimiento de fibroblastos 18 (fgf-18); método para producir la formulación; artículo de manufactura.

Country Status (32)

Country Link
US (2) US9326944B2 (es)
EP (2) EP2720710B1 (es)
JP (1) JP5981538B2 (es)
KR (1) KR102019520B1 (es)
CN (2) CN107715104A (es)
AR (1) AR086956A1 (es)
AU (1) AU2012268987B2 (es)
BR (1) BR112013032400B1 (es)
CA (1) CA2836667C (es)
CL (1) CL2013003618A1 (es)
CO (1) CO6940377A2 (es)
CY (1) CY1117933T1 (es)
DK (1) DK2720710T3 (es)
EA (1) EA024937B1 (es)
EC (1) ECSP14013157A (es)
ES (1) ES2575732T3 (es)
HR (1) HRP20160566T1 (es)
HU (1) HUE028355T2 (es)
IL (1) IL229977A (es)
MX (1) MX338017B (es)
MY (1) MY170630A (es)
PE (1) PE20141265A1 (es)
PH (1) PH12013502529A1 (es)
PL (1) PL2720710T3 (es)
PT (1) PT2720710E (es)
RS (1) RS54875B1 (es)
SG (1) SG195021A1 (es)
SI (1) SI2720710T1 (es)
TW (1) TWI527590B (es)
UA (1) UA113174C2 (es)
WO (1) WO2012172072A1 (es)
ZA (1) ZA201308698B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI527590B (zh) * 2011-06-17 2016-04-01 艾瑞斯貿易公司 Ｆｇｆ－１８之凍乾調配物
BR112016014717B1 (pt) 2013-12-24 2020-12-01 Ares Trading S.A. sistema de gelificação de dois componentes, método para produção de um hidrogel homogêneo, e artigo de produção
CN107209177A (zh) 2015-01-29 2017-09-26 阿雷斯贸易股份有限公司 用于高正电荷蛋白的免疫测定法
CN107921095A (zh) * 2015-08-13 2018-04-17 默克专利有限公司 包含fgf‑18化合物的复方组合物
WO2019063758A1 (en) 2017-09-29 2019-04-04 Merck Patent Gmbh METABOLIC BIOMARKERS FOR PREDICTING RESPONSE TO FGF-18 COMPOUND
WO2019063756A1 (en) 2017-09-29 2019-04-04 Merck Patent Gmbh INFLAMMATORY BIOMARKERS FOR PREDICTING REACTIVITY TO FGF-18 COMPOUND
TWI813597B (zh) * 2017-11-10 2023-09-01 瑞士商諾華公司 用於關節內施用之延長釋放調配物
ES2980597T3 (es) 2018-09-10 2024-10-02 Merck Patent Gmbh Marcadores útiles en las estrategias de enriquecimiento para el tratamiento de la artrosis
CN109836487B (zh) * 2019-03-01 2022-06-17 重庆派金生物科技有限公司 一种人成纤维细胞生长因子18及其可溶性重组表达方法、制备方法、制剂和应用
CN112121150A (zh) * 2019-06-24 2020-12-25 杭州生物医药创新研究中心 一种成纤维细胞生长因子10冻干粉
SI4034115T1 (sl) * 2019-09-25 2025-04-30 Lumosa Therapeutics Co., Ltd. Farmacevtski sestavek, ki obsega konjugat trombolitični peptid-tetrahidroizokinolin
CN113304063A (zh) * 2021-04-23 2021-08-27 四川省恩乐生物工程有限公司 一种用于肌肤美容抗衰老的组合物及其制备方法
CN118310835B (zh) * 2024-04-16 2025-04-11 杭州百凌生物科技有限公司 一种质控品冻干粉及其制备方法和应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217954A (en) * 1990-04-04 1993-06-08 Scios Nova Inc. Formulations for stabilizing fibroblast growth factor
GB9015824D0 (en) 1990-07-18 1990-09-05 Erba Carlo Spa Stable pharmaceutical compositions containing a fibroblast growth factor
DK1516628T3 (da) 1995-07-27 2013-09-08 Genentech Inc Stabil, isotonisk lyofiliseret proteinformulering
US20010056066A1 (en) * 1996-07-26 2001-12-27 Smithkline Beecham Corporation Method of treating immune cell mediated systemic diseases
DE69740074D1 (de) * 1996-10-16 2011-01-20 Zymogenetics Inc Fibroblasten-Wachstumsfaktoren-Homologe
CN1184673A (zh) * 1996-12-13 1998-06-17 中国医科大学 Fgf粗提多肽生长因子混合物及其提取工艺
JP2002527401A (ja) * 1998-10-13 2002-08-27 カイロン コーポレイション Ｆｇｆの脈管形成的に有効な単位用量および投与方法
WO2001039788A2 (en) 1999-12-02 2001-06-07 Zymogenetics, Inc. Methods for targeting cells that express fibroblast growth receptor-3 or-2
CN1303714A (zh) * 2000-01-13 2001-07-18 重庆多泰制药有限公司 Ii型胶原蛋白口服胃溶制剂
WO2002017956A2 (en) * 2000-08-31 2002-03-07 Chiron Corporation Stabilized fgf formulations containing reducing agents
JP4317010B2 (ja) * 2001-07-25 2009-08-19 ピーディーエル バイオファーマ，インコーポレイティド ＩｇＧ抗体の安定な凍結乾燥医薬製剤
DE10204792A1 (de) * 2002-02-06 2003-08-14 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Immuncytokine
AU2003279835B2 (en) 2002-10-07 2009-09-10 Zymogenetics, Inc. Methods of administering FGF18
JP4607010B2 (ja) 2003-02-28 2011-01-05 中外製薬株式会社 タンパク質含有安定化製剤
JP2008500995A (ja) * 2004-06-01 2008-01-17 アレス トレーディング ソシエテ アノニム タンパク質安定化法
EP2586456B1 (en) * 2004-10-29 2016-01-20 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (FGF)
DK1828239T3 (da) 2004-12-10 2011-12-19 Zymogenetics Inc FGF18-produktion i prokaryote værter
KR101378194B1 (ko) * 2005-12-20 2014-03-27 브리스톨-마이어스 스큅 컴퍼니 안정한 단백질 제제
JP4729740B2 (ja) * 2006-01-11 2011-07-20 独立行政法人産業技術総合研究所 受容体特異性を変化させたミュータント増殖因子およびそれを含有する医薬組成物
SI1986612T1 (sl) 2006-02-07 2013-01-31 Shire Human Genetic Therapies, Inc. Stabilizirana spojina glukocerebrosidaze
US8207115B2 (en) 2006-08-25 2012-06-26 Ares Trading S.A. Treatment of cartilage disorders with FGF-18
CN101663046B (zh) * 2007-03-30 2017-07-28 Ambrx公司 经修饰fgf‑21多肽和其用途
EP2068909B1 (en) * 2007-03-30 2012-04-25 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
CN101181280B (zh) * 2007-11-23 2010-07-14 深圳万乐药业有限公司 吡柔比星冻干制剂及其制备方法
AU2008340429C1 (en) * 2007-12-21 2016-09-08 F. Hoffmann-La Roche Ag Antibody formulation
TWI527590B (zh) * 2011-06-17 2016-04-01 艾瑞斯貿易公司 Ｆｇｆ－１８之凍乾調配物

Also Published As

Publication number Publication date
ZA201308698B (en) 2016-02-24
HRP20160566T1 (hr) 2016-06-17
HUE028355T2 (en) 2016-12-28
EP2720710B1 (en) 2016-03-23
IL229977A (en) 2017-01-31
PL2720710T3 (pl) 2016-09-30
PH12013502529A1 (en) 2014-01-27
PT2720710E (pt) 2016-06-17
DK2720710T3 (en) 2016-06-27
TWI527590B (zh) 2016-04-01
PE20141265A1 (es) 2014-09-29
ES2575732T3 (es) 2016-06-30
UA113174C2 (xx) 2016-12-26
CY1117933T1 (el) 2017-05-17
US20160228374A1 (en) 2016-08-11
EP2720710A1 (en) 2014-04-23
US20140121162A1 (en) 2014-05-01
KR102019520B1 (ko) 2019-11-04
MX2013014894A (es) 2014-09-01
JP5981538B2 (ja) 2016-08-31
CA2836667A1 (en) 2012-12-20
MX338017B (es) 2016-03-29
SG195021A1 (en) 2013-12-30
EP3056211A1 (en) 2016-08-17
NZ617992A (en) 2015-09-25
WO2012172072A1 (en) 2012-12-20
US9326944B2 (en) 2016-05-03
BR112013032400B1 (pt) 2021-07-20
BR112013032400A2 (pt) 2016-11-22
AR086956A1 (es) 2014-02-05
JP2014522807A (ja) 2014-09-08
CA2836667C (en) 2020-01-14
CN107715104A (zh) 2018-02-23
RS54875B1 (sr) 2016-10-31
ECSP14013157A (es) 2014-02-28
EA201490032A1 (ru) 2014-05-30
CN103619347A (zh) 2014-03-05
KR20140041600A (ko) 2014-04-04
TW201302217A (zh) 2013-01-16
SI2720710T1 (sl) 2016-07-29
EA024937B1 (ru) 2016-11-30
CO6940377A2 (es) 2014-05-09
MY170630A (en) 2019-08-21
AU2012268987B2 (en) 2016-09-08

Similar Documents

Publication Publication Date Title
CL2013003618A1 (es) Formulacion liofilizada de factor de crecimiento de fibroblastos 18 (fgf-18); método para producir la formulación; artículo de manufactura.
DOP2021000179A (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
PE20181802A1 (es) Derivados de 4-amino-2-(1h-pirazolo[3,4-b]piridin-3-il)-6-oxo-6,7-dihidro-5h-pirrolo[2,3-d]pirimidina y los respectivos (1h-indazol-3-il) derivados como moduladores cgmp para el tratamiento de enfermedades cardiovasculares
MY164274A (en) Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
CL2015002725A1 (es) Compuestos aromáticos sustituidos para el tratamiento de la fibrosis pulmonar, la fibrosis hepática, la fibrosis de la piel y la fibrosis cardíaca
IN2015DN00017A (es)
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
IN2015DN02573A (es)
ECSP15031579A (es) Lactamas Fusionadas de Arilo y Heteroarilo
CL2014000931A1 (es) Compuestos derivados de 5,7-imidazo[1,2-c]pirimidina sustituida, inhibidores de las cinasas jak; proceso de preparacion; composicion farmaceutica; metodo para el tratamiento de enfermedades autoinmunitarias, inflamatorias, rechazo de trasplante de organos y neoplasias.
EA201790246A1 (ru) Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы
EA201290988A1 (ru) Стереоселективный синтез фосфорсодержащих активных соединений
EA201390010A1 (ru) Замещенные триазолопиридины
EA201491623A1 (ru) Замещенные пирролидин-2-карбоксамиды
EP2787082A4 (en) MICRO-ORGANISMS FOR THE SIMULTANEOUS PREPARATION OF L-AMINO ACID AND RIBOFLAVIN AND METHOD FOR THE PREPARATION OF L-AMINO ACID AND RIBOFLAVIN THEREWITH
UY36118A (es) Compuestos y composiciones para inducir condrogénesis
MX373650B (es) Triheptanoina para el tratamiento de la deficiencia del transportador de glucosa 1.
AR099557A1 (es) Fgf-18 en trasplantes de injertos y procedimientos de ingeniería de tejido
BR112016023498A2 (pt) composições para higiene bucal
MX2016008496A (es) Composiciones de acido graso de liberacion controlada para usarse en recontruccion corporal y formacion del cuerpo.
WO2010108058A3 (en) Small molecule inhibitors of dusp6 and uses therefor
MX375204B (es) Formulación de factor de crecimiento de fibroblastos 18 en geles de xiloglucano.
IN2013DN02555A (es)
EA201591704A1 (ru) Новые устойчивые соли пентадекапептида, способ их получения, их применение в производстве фармацевтических составов и их применение в терапии
DOP2019000305A (es) Compuestos y composiciones para inducir la condrogénesis